This company listing is no longer active
IMMP.F Stock Overview
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.085 |
| 52 Week High | UK£0.10 |
| 52 Week Low | UK£0.073 |
| Beta | 1.11 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -26.72% |
| 5 Year Change | -88.19% |
| Change since IPO | -87.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMMP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -1.7% |
| 1Y | n/a | 14.6% | 22.9% |
Return vs Industry: Insufficient data to determine how IMMP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IMMP.F performed against the US Market.
Price Volatility
| IMMP.F volatility | |
|---|---|
| IMMP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 14 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
ImmuPharma plc Fundamentals Summary
| IMMP.F fundamental statistics | |
|---|---|
| Market cap | US$19.62m |
| Earnings (TTM) | -US$9.70m |
| Revenue (TTM) | US$140.48k |
141.5x
P/S Ratio-2.0x
P/E RatioIs IMMP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMP.F income statement (TTM) | |
|---|---|
| Revenue | UK£118.35k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£118.35k |
| Other Expenses | UK£8.29m |
| Earnings | -UK£8.17m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 100.00% |
| Net Profit Margin | -6,906.55% |
| Debt/Equity Ratio | 0.01% |
How did IMMP.F perform over the long term?
See historical performance and comparison